Active not recruitingOBSERVATIONAL

LEVANTIS-0093A: GAGomes for Multi-Cancer Early Detection in High-Risk Adults (LEV93A)

This study, called LEVANTIS-0093A, is exploring new ways to find early signs of different cancers in adults aged 55 to 80. Specifically, it focuses on people who have a significant history of smoking. The main goal is to test a new blood-based screening method that aims to detect cancer much earlier. Researchers are using blood samples already collected as part of the Yorkshire Lung Screening Trial and the Yorkshire Kidney Screening Trial. This approach helps scientists understand how these new tests work in a real-world setting, with the hope of developing better tools for early cancer detection in the future. The project is led by the University of Leeds and funded by Yorkshire Cancer Research.

At a glance

Status

Active not recruiting

Sponsor

Elypta

Enrolment target

1,235

Start

14 Mar 2022

Estimated completion

01 Mar 2026

Cancer

What is this study about?

This study is called LEVANTIS-0093A, and it's looking into an exciting area of cancer research: finding cancer early, possibly even before symptoms appear. This is really important because finding cancer at an early stage often means treatments are more effective and people have better outcomes. The study is focusing on a new blood test designed to spot tiny clues, known as 'GAGomes', that might indicate cancer is present.

The researchers are studying adults between 55 and 80 years old who have a history of smoking. This is because people with a significant smoking background have a higher risk of developing certain cancers. Instead of recruiting new participants, this study is making smart use of blood samples and information that have already been collected from people taking part in other important health studies in Yorkshire – the Yorkshire Lung Screening Trial and the Yorkshire Kidney Screening Trial. This helps researchers work efficiently and means fewer new demands on volunteers.

The main aim is to check how well this new blood test works at finding different types of cancer. By comparing the results of the blood tests with the health information of the people whose samples are being used, scientists hope to confirm if this new method can accurately detect cancer early. This research, funded by Yorkshire Cancer Research and involving universities in Leeds and Manchester, is a key step towards potentially offering better early detection options for cancer in the future.

Key takeaways

Studies a new blood test to find early signs of multiple cancers.
Focuses on adults aged 55-80 with a history of smoking.
Uses existing blood samples and data from other Yorkshire screening trials.
No new procedures or visits required for participants.
Aims to improve future cancer early detection methods.
Funded by Yorkshire Cancer Research and involves leading universities.

Who may be eligible?

To be part of this study, you would generally need to be an adult between 55 and 80 years old. A significant part of the criteria revolves around your smoking history. This means you would either be a current smoker or someone who has quit smoking within the last 15 years, and you would also need to meet specific measures of how much you've smoked over your lifetime, or have a certain calculated risk of lung cancer.

Crucially, this study doesn't involve new volunteers directly. Instead, it's using information and blood samples from people who have already agreed to take part in two other important studies led by the University of Leeds: the Yorkshire Lung Screening Trial (YLST) and the Yorkshire Kidney Screening Trial (YKST). This means you would already need to be a part of both of these pre-existing studies and have given your permission for your samples and data to be used in this way.

You wouldn't be able to be included if it's considered unsafe for you to provide a blood sample, or if you had not agreed to take part in the YKST trial. If you were already medically considered unfit for sample collection through the existing studies, you would also not be included in this specific research.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you between 55 and 80 years old?
Do you have a history of smoking (current or quit within 15 years, with a certain smoking amount or risk score)?
Are you already participating in both the Yorkshire Lung Screening Trial AND the Yorkshire Kidney Screening Trial?
Have you already given your consent for your samples and data from these trials to be used for further research?
Are you medically fit enough for blood sample collection (which would have been assessed during the original trials)?
Are you NOT just participating in the Yorkshire Lung Screening Trial without also being part of the Kidney Screening Trial?

Answer every question to see your result.

What does participation involve?

If you are already part of the Yorkshire Lung Screening Trial (YLST) and the Yorkshire Kidney Screening Trial (YKST) and have given your permission for your information and samples to be used for research, your participation in this study is quite indirect. You wouldn't need to visit any clinics or undergo new tests specifically for LEVANTIS-0093A.

The researchers will use blood samples that you have already provided for the YLST Biomarker sub-study. They will also use your health information and data that has already been collected through the YLST and YKST. This means you won't have any extra appointments, follow-up calls, or new procedures related to this particular study. Your involvement has already happened when you participated in the original screening trials and agreed to the use of your samples for further research. The total duration of *your direct involvement* was when you participated in the initial screening trials.

Potential risks and benefits

Since this study uses samples and data already collected from other trials, there are no new direct risks to you. You won't undergo any additional procedures. The potential benefits are for the wider community: the hope that this research will lead to better, earlier detection methods for cancer, which could save lives in the future. You always have the right to withdraw your consent for your stored samples and data to be used for future research, even if you previously agreed. You would need to contact the organisers of the original Yorkshire Lung Screening Trial or Yorkshire Kidney Screening Trial if you wished to do this.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Leads Teaching Hospitals Trust
Verified postcode
Leeds, United Kingdom

Common questions

What is a 'GAGome' test?

It's a new type of blood test that looks for tiny changes in your body that might show early signs of cancer.

Why are they only studying people who smoke?

People with a significant smoking history have a higher risk of certain cancers, so this study focuses on this group to understand how the test works best.

Do I need to do anything to participate?

No, if you're already in the Yorkshire Lung and Kidney Screening Trials and gave permission for research, your existing samples are used. No new actions are needed from you.

What do the researchers hope to find?

They hope to prove that this new blood test can reliably find early signs of different cancers, which could lead to better screening in the future.

Who is funding this research?

This important cancer research is funded by Yorkshire Cancer Research and involves the University of Leeds, the University of Manchester, and Leeds Teaching Hospitals.